EFFICACY AND SAFETY OF NATALIZUMAB TREATMENT FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS: INTERIM RESULTS OF THE TYSABRI® OBSERVATIONAL PROGRAMME IN THE UK

被引：2
|
作者：
Hanna, Jerome [1 ]
Rosen, Jan Paul [1 ]
Smethurst, Caroline [1 ]
机构：
[1] Biogen Idec Ltd, Maidenhead, Berks, England
来源：
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY | 2013年 / 84卷 / 11期
关键词：
D O I：
10.1136/jnnp-2013-306573.179
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis
    Gajofatto, Alberto
    Turatti, Marco
    Monaco, Salvatore
    Benedetti, Maria Donata
    DRUG HEALTHCARE AND PATIENT SAFETY, 2015, 7 : 157 - 167
  • [32] Immunogenicity of alemtuzumab treatment for relapsing-remitting multiple sclerosis: no effect on efficacy or safety
    Selmaj, K.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S247 - S247
  • [33] TYSABRI® Observational Program: Long-term Safety and Effectiveness in Relapsing-Remitting Multiple Sclerosis over 15 years
    Trojano, M.
    Wiendl, H.
    Butzkueven, H.
    Kappos, L.
    Spelman, T.
    Bodhinathan, K.
    Sun, Z.
    Drenth, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 737 - 737
  • [34] Efficacy and Safety of Oral Therapies for Relapsing-Remitting Multiple Sclerosis
    Paolicelli, Damiano
    Manni, Alessia
    Iaffaldano, Antonio
    Trojano, Maria
    CNS DRUGS, 2020, 34 (01) : 65 - 92
  • [35] Efficacy and Safety of Oral Therapies for Relapsing-Remitting Multiple Sclerosis
    Damiano Paolicelli
    Alessia Manni
    Antonio Iaffaldano
    Maria Trojano
    CNS Drugs, 2020, 34 : 65 - 92
  • [36] Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life
    Planas, Raquel
    Martin, Roland
    Sospedra, Mireia
    PATIENT-RELATED OUTCOME MEASURES, 2014, 5 : 25 - 33
  • [37] Natalizumab Discontinuation: Observational Study of University of Colorado Patients with Relapsing-Remitting Multiple Sclerosis
    Nnunukwe, Ngozi
    Schreiner, Teri
    NEUROLOGY, 2012, 78
  • [38] Safety and efficacy of helminth treatment in relapsing-remitting multiple sclerosis: Results of the HINT 2 clinical trial
    Fleming, John
    Hernandez, Gianna
    Hartman, Leslie
    Maksimovic, Jane
    Nace, Sara
    Lawler, Benjamin
    Risa, Todd
    Cook, Thomas
    Agni, Rashmi
    Reichelderfer, Mark
    Luzzio, Christopher
    Rolak, Loren
    Field, Aaron
    Fabry, Zsuzsanna
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 (01) : 81 - 91
  • [39] Subcutaneously delivered natalizumab for the treatment of highly active relapsing-remitting multiple sclerosis
    Haluskova, S.
    Valis, M.
    CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE, 2022, 85 (03) : 206 - 212
  • [40] Effects of natalizumab on work ability in patients with relapsing-remitting multiple sclerosis: results from the WANT observational study
    Capra, R.
    De Rossi, N.
    Masera, S.
    Zipoli, V.
    Morra, V. Brescia
    Mirabella, M.
    Patti, F.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 264 - 265
12345